- Drug candidate PXT3003, in a Phase 3
trial for the treatment of Charcot-Marie-Tooth disease type 1A,
will be highlighted in six posters and two oral
presentations
- Drug candidate PXT864, in clinical
development for the treatment of Alzheimer’s disease, will be
highlighted in two posters and three oral presentations
Regulatory News:
Pharnext SA (FR0011191287 - ALPHA) (Paris:ALPHA),
a biopharmaceutical company pioneering a new approach to the
development of innovative drug combinations based on big data
genomics and artificial intelligence, today announced its upcoming
participation in five international scientific conferences in June
and July 2018 throughout Europe and the United States.
Pharnext will share the latest scientific and clinical data
regarding PXT3003, a drug candidate which is currently being
evaluated in an ongoing international pivotal Phase 3 trial for the
treatment of Charcot-Marie-Tooth disease type 1A. Pharnext will
also illustrate the benefits of its disruptive R&D approach
PLEOTHERAPY™ in developing drug combinations, and discuss the
Company’s Phase 2 trial of PXT864 for the treatment of Alzheimer’s
disease.
The company will attend the following events:
European Academy of Neurology (EAN) congressJune 16-18,
2018 in Lisbon, Portugal
Two ePosters (oral communications)
#EPR1170
A multicenter, double-blind,
placebo-controlled, pivotal phase III study (PLEO-CMT) of a fixed
combination of baclofen, naltrexone and sorbitol (PXT3003) for
Charcot-Marie-Tooth Disease Type 1A (CMT1A).
Presenter: Dr René Goedkoop, MD, Chief Medical Officer,
Pharnext, France Room Session EPR122 / Screen B12 Date/Time
June 16, 2018, 13:30 - 14:15 CEST #EPR1007
Double-blind argument for a synergistic
therapeutic effect of a fixed low-dose combination of acamprosate
and baclofen in Alzheimer's disease.
Presenter: Dr René Goedkoop, MD, Chief Medical Officer,
Pharnext, France Room Session EPR101 / Screen A1 Date/Time
June 16, 2018, 13:30 - 14:15 CEST
International Congress on Neuromuscular Diseases
(ICNMD)July 6-10, 2018 in Vienna, Austria
Two Posters
#545 Baclofen, naltrexone and sorbitol all contribute to the
efficacy of PXT3003 in CMT1A rats. Authors T. Prukop et al.
Room Mezzanine Floor Gallery and Foyers Date/Time
July 8, 2018, 5:15pm - 6:30pm CEST #728
Baclofen, naltrexone and sorbitol all
contribute to PXT3003-induced myelination in CMT1A DRG
co-cultures.
Authors N. Cholet et al. Room Session Room 1
Date/Time July 8, 2018, 5:15pm - 6:30pm CEST
Innovations and State of the Art In Dementia Research meeting
(ISADR)July 16-18, 2081 in Valencia, Spain
Two Oral Communications
Cmax-based synergistic therapeutic effect
on cognitive disability in mild Alzheimer’s disease after 36 weeks
treatment with baclofen and acamprosate.
Presenter: Prof Jacques Touchon, MD, PhD, Faculteì de
Meìdecine de Montpellier, France Date/Time July 16, 2018,
11:35am - 11:55am CEST A potential tri-therapy for
Alzheimer’s disease. Presenter: Dr Rodolphe Hajj, PhD, Chief
Pharmacology Officer, Pharnext, France Date/Time July 16,
2018, 12:55pm - 1:15pm CEST
Peripheral Nerve Society (PNS) congressJuly 22-25, 2018
in Baltimore, US
One Oral Communication
Status of the Pivotal Phase III Study of
PXT3003 for Charcot-Marie-Tooth Type 1A disease (CMT1A).
Presenter: Dr René Goedkoop, MD, Chief Medical Officer,
Pharnext, France Date/Time July 23, 2018, 2.45pm - 3.00pm
EST
Four Posters
#20 Baclofen, naltrexone and sorbitol all contribute to the
efficacy of PXT3003 in CMT1A rats. Authors R. Hajj et al.
Session Session 1 Date/Time July 22, 2018 #45
Status of the Pivotal Phase III Study of
PXT3003 for Charcot-Marie-Tooth Type 1A disease(CMT1A)
Authors R. Goedkoop et al. Session Session 2
Date/Time July 23, 2018 #85
Synergy of baclofen, naltrexone and
sorbitol (PXT3003) in Charcot-Marie-Tooth Type 1A (CMT1A)
Authors J. Laffaire et al Session Session 2 Date/Time
July 23, 2018 #1
Baclofen, naltrexone and sorbitol all
contribute to PXT3003-induced myelination in CMT1A DRG
co-cultures
Authors R. Hajj et al. Session Session 3 Date/Time July 24, 2018
Alzheimer's Association International Conference
(AAIC)July 22-26, 2018 in Chicago, US
Two Posters
#P1-061
Double-blind argument for a synergistic
therapeutic effect of a fixed low-dose combination of acamprosate
and baclofen in Alzheimer’s Disease
Authors J-M Orgogozo et al Session Session P1-01 /
Hall F1 Date/Time July 22, 2018, 9:30am - 4:15pm EST #P3-042
PXT864 combination restores cognitive
deficits of Alzheimer’s mice, even in animals with advanced disease
that lost responsiveness to donepezil.
Authors A. Brureau et al. Session Session P3-02, Hall
F1 Date/Time July 24, 2018, 9:30am - 4:15pm EST
If you are interested in meeting the Pharnext team during either
of these events or if you need more information about Pharnext’s
participation, please send an email to contact@pharnext.com
About PharnextPharnext is an advanced clinical-stage
biopharmaceutical company developing novel therapeutics for orphan
and common neurodegenerative diseases that currently lack curative
and/or disease-modifying treatments. Pharnext has two lead products
in clinical development. PXT3003 is currently in an international
Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type
1A and benefits from orphan drug status in Europe and the United
States. The results of this trial are expected in the second half
of 2018. PXT864 has generated positive Phase 2 results in
Alzheimer’s disease. Pharnext has developed a new drug discovery
paradigm based on big genomic data and artificial intelligence:
PLEOTHERAPY™. The Company identifies and develops synergic
combinations of drugs called PLEODRUG™ offering several key
advantages: efficacy, safety and robust intellectual property. The
Company was founded by renowned scientists and entrepreneurs
including Professor Daniel Cohen, a pioneer in modern genomics and
is supported by a world-class scientific team.
Pharnext is listed on Euronext Growth Stock Exchange in Paris
(ISIN code: FR0011191287).For more information, visit
http://www.pharnext.com/
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180611005795/en/
PharnextXavier Paoli, +33 (0)1 41 09 22 30Chief
Commercial Officercontact@pharnext.comorFinancial Communication
(France)ActifinStéphane Ruiz, +33 (0)1 56 88 11
15sruiz@actifin.frorInvestor Relations (U.S.)Stern Investor
Relations, Inc.Matthew Shinseki, +1 212 362
1200matthew@sternir.comorInvestor Relations (Europe)MC
Services AGAnne Hennecke, +49 211 529252
22anne.hennecke@mc-services.euorMedia Relations
(Europe)Ulysse CommunicationBruno Arabian, +33 (0)1 81 70 96
30barabian@ulysse-communication.comorMedia
Relations (U.S.)RooneyPartnersKate L. Barrette, +1 212 223
0561kbarrette@rooneyco.com
Pharnext (EU:ALPHA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pharnext (EU:ALPHA)
Historical Stock Chart
From Sep 2023 to Sep 2024